The presence of clonal hematopoiesis of indeterminate potential (CHIP) was associated with increased susceptibility to trastuzumab-related cardiotoxic effects.
Does the presence of CHIP increase susceptibility to trastuzumab-related cardiotoxic effects?
The presence of clonal hematopoiesis of indeterminate potential (CHIP) may serve as a risk factor for developing cardiotoxicity in patients treated with trastuzumab.
Absolute Event Rate: 0% vs 0%
In this cohort study, the presence of CHIP was associated with increased susceptibility to trastuzumab-related cardiotoxic effects.
Park et al. (Thu,) reported a other. The presence of clonal hematopoiesis of indeterminate potential (CHIP) was associated with increased susceptibility to trastuzumab-related cardiotoxic effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: